TSE:2914

Japan Tobacco Inc. (JT) announced it will receive a dividend of USD 710 million (approximately JPY 110.1 billion) from its consolidated subsidiary, JT International Holding B.V., following a board resolution on March 24, 2026.

The dividend is expected to be received on March 26 and will be recorded as non-operating income in JT’s non-consolidated financial statements for fiscal year 2026.

However, the company stated that the payment will not have a material impact on its consolidated financial results, as it is an internal transaction within the group.
💬 🔗
Author
The Investor 03-25-26
Japan Tobacco Inc. has completed the transfer of its pharmaceutical business to Shionogi & Co., Ltd., finalizing its exit from this segment.

The transaction was executed through a simplified absorption-type split, under which Shionogi assumed full ownership of JT Group’s pharmaceutical operations in line with previously announced agreements. As a result, JT is now fully focused on its core businesses, primarily tobacco and processed food, while Shionogi expands its pharmaceutical portfolio through the integration of the transferred operations.
💬 🔗
Author
The Investor 01-02-26
Japan Tobacco Inc. announced that it has completed the transfer of its pharmaceutical business to Shionogi & Co., Ltd. as of December 1, 2025. The move was executed through a company simplified absorption-type split, following agreements announced in May and September 2025.

The divestment marks JT’s full exit from pharmaceuticals as the company sharpens its focus on its core tobacco and processed food businesses. JT, which operates in more than 130 markets and employs about 53,000 people worldwide, said the transfer aligns with its long-term strategy to strengthen value creation across its main business segments.
💬 🔗
Author
WS Investor 12-03-25